Dynavax’s Heplisav Heads To Advisory Panel, But Will It Drudge Up Old Safety Issues?
This article was originally published in The Pink Sheet Daily
Executive Summary
Company says its hepatitis B vaccine, which had been placed on clinical hold at one point during its Phase III trials, will be discussed at a FDA advisory committee in November.